Benefit Across All Patient Subgroups
The data presented by Revolution Medicines at the ESMO Congress in Madrid on Friday came from a late-stage trial of 500 previously treated patients, 248 of whom received Rasonque and 252 chemotherapy. Key findings include:
- Rasonque cut the risk of death versus chemotherapy by 39% to 68% across all evaluated RAS-mutant subgroups.
- In patients with no identified RAS mutation, the risk of death fell by 57%.
- The drug improved survival compared with several different standard chemotherapy regimens.
Survival benefits were also seen in patients whose cancer spread within six months of earlier therapy and in those who had received only one prior treatment for metastatic disease. These are exploratory analyses, but experts regard the consistency of the results across many groups as encouraging.
Targeting the “Heart” of the Tumour
RAS mutations drive tumour growth and are found in more than 90% of pancreatic cancer cases. Rasonque is a multi-selective inhibitor of RAS in its active state, taken as a once-daily pill, targeting the “switched-on” forms of RAS proteins that drive the growth of most pancreatic tumours.

















